Insulin Degludec Injection, Solution
Product Images NDC 50090-7175

Product Visual Gallery

This gallery contains 61 technical images submitted to the FDA as part of the official labeling for Insulin Degludec (NDC 50090-7175). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Structural Formula Of Tresiba (Image 01)

Chemical structure diagram of insulin degludec showing the amino acid sequences and molecular bonds in its A and B chains.*

FDA Label Image

Figure 2: Mean Gir Profile For 0.4 U/kg Dose Of Tresiba (steady State) In Patients With Type 1 Diabetes Mellitus (Image 02)

A line graph showing glucose infusion rate (GIR) over time since injection (hours) for Insulin Degludec at a dose of 0.4 U/kg. The graph displays a shaded area indicating the 24-hour interval, with GIR levels rising initially, peaking around 6-12 hours, and gradually declining afterward up to 42 hours.*

FDA Label Image

Vial Ifu-1 (Image 03)

An illustration of a vial labeled with the text "Tamper resistant cap (rubber stopper under cap)." The vial is depicted with a cap designed to resist tampering and a rubber stopper positioned beneath the cap.*

FDA Label Image

Vial Ifu-2 (Image 04)

An illustration showing a hand holding a small vial, typically used for injectable medication. The image likely represents the vial of Insulin Degludec injection, solution for subcutaneous use at 200 U/mL strength from A-S Medication Solutions.*

FDA Label Image

Vial Ifu-figure A,b (Image 05)

Illustration showing a two-step process of preparing an insulin injection. The first frame depicts a hand removing a cap or protective cover from a vial or insulin pen. The second frame shows the hand pulling back or adjusting a component, likely to prepare the injection device for use. No text or branding is visible.*

FDA Label Image

Vial Ifu-figure C (Image 06)

An instructional illustration showing the process of preparing an insulin injection. It depicts a hand holding an insulin vial and another hand attaching or detaching a syringe needle. A small inset image shows a close-up of the syringe.*

FDA Label Image

Vial Ifu-figure D (Image 07)

An instructional diagram depicting a hand holding a vial and another hand attaching a needle or drawing medication from the vial. The image shows the correct positioning and attachment method, indicated by an arrow pointing to the connection area.*

FDA Label Image

Vial Ifu-figure E (Image 08)

An instructional illustration showing a hand holding a vial with the other hand positioning a syringe needle above the vial's rubber stopper, indicating the injection of air into the vial or preparation for drawing medication. The illustration features arrows guiding the motion.*

FDA Label Image

Vial Ifu-figure F (Image 09)

An instructional diagram showing a hand holding a syringe and inserting the needle into a vial cap, with a downward arrow indicating the direction of insertion. This likely illustrates the step of drawing insulin degludec injection solution from the vial before subcutaneous administration.*

FDA Label Image

Vial Ifu-figure G (Image 10)

An instructional illustration showing a person holding an insulin vial and using a syringe to draw the insulin solution. The hand on the vial rotates it while the other hand holds the syringe below, indicating preparation for injection.*

FDA Label Image

Vial Ifu-figure H (Image 11)

An instructional illustration showing a hand holding a vial or cartridge while pushing a plunger downward. The inset shows a close-up of the vial or cartridge, focusing on its markings or stopper.*

FDA Label Image

Vial Ifu-figure I (Image 12)

Instructional diagram showing a hand holding a syringe above a vial, with an arrow indicating the action of drawing liquid from the vial into the syringe. No text or branding is visible.*

FDA Label Image

Vial Ifu-figure J (Image 13)

Illustration showing common injection sites for subcutaneous injection in humans, highlighting areas on the abdomen, thighs, and upper arms on front and back views of the body.*

FDA Label Image

Vial Ifu-figure K (Image 14)

Instructional illustration showing a hand holding an injection device at an angle to the skin, with an arrow indicating the direction to insert the needle for a subcutaneous injection.*

FDA Label Image

Vial Ifu-figure L (Image 15)

An instructional illustration showing a hand holding an injection device above the skin with an arrow indicating the direction of injection, representing a subcutaneous injection technique for insulin degludec solution.*

FDA Label Image

Figure A: Novofine Needle Components (Image 16)

An instructional diagram labeled NovoFine showing components of a needle assembly including an outer needle cap, inner needle cap, needle, and a paper tab, arranged from left to right.*

FDA Label Image

Figure A: Novotwist Needle Components (Image 17)

Illustration showing the components of a NovoTwist needle: outer needle cap, inner needle cap, needle, and a paper tab. The diagram visually separates each part for assembly or usage understanding.*

FDA Label Image

Figure A (Image 18)

Illustration of an insulin injection pen labeled Insulin Degludec Injection FlexTouch, 200 U/mL strength, highlighting components: pen cap, insulin scale, insulin window, dose counter, dose pointer, dose selector, and dose button. The pen is shown disassembled with the cap removed on the left and the dose adjustment end on the right.*

FDA Label Image

100 U/ml Ifu (Figure B)

An instructional illustration labeled 'Figure B' showing hands holding a pen-like device, with an arrow indicating the removal of a protective cap or cover from the device tip.*

FDA Label Image

100 U/ml Ifu (Figure C)

An instructional diagram depicting a hand holding a pen-like injection device, specifically showing the grip and positioning of the insulin degludec 200 U/mL pen for subcutaneous injection. The image focuses on the device's barrel and tip, illustrating how it should be held during administration.*

FDA Label Image

100 U/ml Ifu (Figure D)

An instructional diagram showing hands adjusting or twisting parts of NovoFine and NovoTwist needles, with arrows indicating the direction of the motion. The illustration is labeled as Figure D and demonstrates use steps for these insulin injection needles.*

FDA Label Image

100 U/ml Ifu (Figure E)

An instructional illustration showing how to use the NovoFine and NovoTwist needles. The two-panel diagram demonstrates the proper attachment method of these needles to an insulin pen, depicting hand positioning and needle insertion steps for injection preparation.*

FDA Label Image

100 U/ml Ifu (Figure F)

Instructional diagram showing how to attach a NovoFine needle to a NovoTwist injection pen for subcutaneous administration of insulin degludec injection, solution 200 U/mL from A-S Medication Solutions. The illustration guides on the proper connection step for the injection device.*

FDA Label Image

100 U/ml Ifu (Figure G)

Instructional illustration showing the connection of a needle to the insulin pen device. The image demonstrates attaching the needle by aligning and pushing it onto the pen, accompanied by directional arrows highlighting the action.*

FDA Label Image

100 U/ml Ifu (Figure H)

An instructional diagram showing a close-up of a dose selection knob on an injection pen. The dial displays a dose of '2' units selected, with arrows indicating the direction to turn the knob. The illustration highlights adjusting the dose for subcutaneous injection.*

FDA Label Image

100 U/ml Ifu (Figure I)

An instructional illustration showing a hand holding an insulin pen injection device. The focus is on the pen's tip, indicating a step in the injection process, possibly priming or dialing dose.*

FDA Label Image

100 U/ml Ifu (Figure J)

An instructional illustration showing a hand holding an insulin degludec injection pen. The image focuses on a step where a component is being pulled upward, indicated by a large black arrow pointing up below the pen. An inset magnifies the pen's dial area, highlighting details of the dosing mechanism. This diagram assists with proper handling or preparation of the injection pen.*

FDA Label Image

100 U/ml Ifu (Figure K)

An instructional illustration showing the dose selection step for an injection pen. The diagram includes images of the dose selector dial, highlighting examples of 5 units and 24 units selected for injection dose adjustment.*

FDA Label Image

100 U/ml Ifu (Figure L)

Insulin Degludec 200 U/mL injection solution in a prefilled pen syringe. The visible portion shows a graduated dose window with markings and an approximate 200 units dose left. The pen is designed for subcutaneous use and labeled by A-S Medication Solutions.*

FDA Label Image

100 U/ml Ifu (Figure M)

An instructional illustration showing front and back views of a human body with highlighted areas indicating recommended subcutaneous injection sites for insulin degludec. Injection sites include the abdomen, thighs, upper arms, and buttocks.*

FDA Label Image

100 U/ml Ifu (Figure N)

Illustration showing a hand holding a yellow insulin injection pen with the thumb pressing down on the plunger end, and a large blue downward arrow indicating the injection or dispensing direction. The figure is labeled as "Figure N."*

FDA Label Image

100 U/ml Ifu (Figure O)

An instructional illustration showing a hand holding a syringe to inject insulin into the subcutaneous tissue of the forearm. The image includes an inset zoom showing the injection angle of 0 degrees, with an arrow indicating injection direction downward into the skin.*

FDA Label Image

100 U/ml Ifu (Figure P)

Instructional illustration showing a hand holding a vial or tube filled with yellow liquid. The hand is positioned vertically with the thumb on top and fingers around the bottom. A speech bubble indicates counting slowly from 1 to 6, suggesting a timing or measurement step in preparation or usage of the product.*

FDA Label Image

100 U/ml Ifu (Figure Q)

An instructional diagram showing a subcutaneous injection device with an upward-pointing arrow, likely indicating the direction to pull or remove a component of the insulin degludec injection pen.*

FDA Label Image

100 U/ml Ifu (Figure R)

An instructional illustration showing the use of NovoFine and NovoTwist injection needles. The image depicts how to attach these needles to an insulin pen and the direction in which to twist or pull them for proper use.*

FDA Label Image

100 U/ml Ifu (Figure S)

An instructional diagram shows how to attach a needle to a syringe by aligning and pressing the needle cap onto the syringe tip, with arrows indicating the direction of attachment.*

FDA Label Image

100 U/ml Ifu (Figure T)

An instructional illustration showing a close-up of hands manipulating a syringe or pen device. One hand is holding the device steady while the other hand is pulling or attaching a yellow or greenish component, possibly a safety cap or needle cover, indicated by a blue arrow pointing to the movement direction.*

FDA Label Image

U200 Figure A (Image 38)

An instructional labeled diagram of an Insulin Degludec 200 units/mL injection pen by A-S Medication Solutions. The diagram identifies key parts of the pen: pen cap, insulin scale, insulin window, dose counter, dose pointer, dose selector, and dose button, illustrating components used for dosing and delivery of the subcutaneous injection solution.*

FDA Label Image

Figure A: Novofine Needle Components (Image 40)

An instructional illustration showing the parts of a NovoFine needle assembly for injection, including the outer needle cap, inner needle cap, needle, and paper tab. These components are labeled and displayed in a separated, exploded view format.*

FDA Label Image

Figure A: Novotwist Needle Components (Image 41)

An instructional diagram titled NovoTwist showing components of a needle assembly: outer needle cap, inner needle cap, needle, and paper tab arranged sequentially from left to right.*

FDA Label Image

200 U/ml Ifu Figure B (Image 43)

An instructional illustration showing a close-up of hands performing a step to remove or attach a cap or protective cover on a medical injection device, likely demonstrating preparation for subcutaneous administration.*

FDA Label Image

200 U/ml Ifu Figure C (Image 44)

An instructional illustration showing a close-up of an insulin degludec injection pen with a finger pressing the dose button. The image likely demonstrates how to administer a subcutaneous injection.*

FDA Label Image

200 U/ml Ifu Figure D (Image 45)

Illustration showing hands interacting with a NovoFine or NovoTwist needle, depicting the process of removing or attaching the needle cap with arrows indicating the direction of movement.*

FDA Label Image

200 U/ml Ifu Figure E (Image 46)

Illustration depicting the use of NovoFine and NovoTwist devices, showing how to hold and twist the components together for preparation or administration. The image is instructional and relevant for users of injection devices associated with insulin products.*

FDA Label Image

200 U/ml Ifu Figure F (Image 47)

An instructional diagram showing how to connect a NovoFine needle to a NovoTwist injection pen, illustrating the attachment process with directional arrows.*

FDA Label Image

200 U/ml Ifu Figure G (Image 48)

An instructional illustration depicting the use of NovoFine and NovoTwist pen needles for insulin injection. The two panels show hand positioning and attachment techniques for these subcutaneous injection devices, indicated by arrows guiding the steps.*

FDA Label Image

200 U/ml Ifu Figure H (Image 49)

An instructional illustration showing a person adjusting the dose selector on a blue insulin pen, selecting 2 units for injection. The image highlights the dosage window displaying '0.4' units and indicates subcutaneous injection preparation for insulin degludec.*

FDA Label Image

Figure 3 (Image 52)

A line graph comparing the percentage of subjects experiencing an event over 30 months for treatments with Insulin Degludec (IDeg) and Insulin Glargine (IGlar). The x-axis represents time to first event in months, and the y-axis shows the percentage of subjects with an event. The graph includes a hazard ratio of 0.91 with a 95% confidence interval from 0.78 to 1.06.*

FDA Label Image

200 U/ml Ifu Figure I (Image 53)

An instructional illustration showing a hand holding and slightly shaking a green insulin degludec injection pen with a visible cartridge inside, preparing it for subcutaneous use.*

FDA Label Image

200 U/ml Ifu Figure J (Image 54)

An instructional diagram illustrating a hand holding an insulin degludec injection pen. The image shows a close-up of the pen's dial, with an arrow indicating rotation or adjustment, and an upward arrow suggesting insertion or setting action.*

FDA Label Image

200 U/ml Ifu Figure K (Image 55)

An instructional diagram showing a close-up of a hand holding an insulin pen injector labeled with a 'U-200' marking. The diagram includes a detailed view of the dosage selector window displaying example dose settings of 6 units and 24 units, with arrows indicating dose adjustment instructions.*

FDA Label Image

200 U/ml Ifu Figure L (Image 56)

An instructional drawing illustrating a syringe or pen injector device with a dosage scale marked in units from 0 to example 400 units on the left side, designed for subcutaneous injection. The diagram highlights the approximate dosing scale on the device, related to insulin degludec 200 U/mL solution injection.*

FDA Label Image

200 U/ml Ifu Figure M (Image 57)

A line drawing illustration showing the front and back views of a human body with highlighted areas indicating recommended injection sites for subcutaneous administration. The highlighted areas include the abdomen, upper arms, front and outer sides of thighs, and upper buttocks or lower back region.*

FDA Label Image

200 U/ml Ifu Figure N (Image 58)

An instructional illustration showing a hand holding an insulin pen injection device vertically with the cap removed. A downward-pointing arrow below the pen indicates the direction of holding or injecting the device, likely to guide proper use of the insulin degludec injection pen.*

FDA Label Image

200 U/ml Ifu Figure O (Image 59)

An instructional illustration demonstrates the proper technique for using an insulin pen. It shows a hand holding the pen and pressing the plunger down, with an arrow indicating downward movement. A close-up inset depicts the pen's dial showing zero units, indicating the dosing step.*

FDA Label Image

200 U/ml Ifu Figure P (Image 60)

An instructional illustration showing a hand holding an injection pen with a dial display. The dial indicates counting slowly from 1 to 6, presumably instructing slow dose dialing or injection steps, accompanied by a speech bubble with the numbers 1 to 6 inside.*

FDA Label Image

200 U/ml Ifu Figure Q (Image 61)

Illustration showing a subcutaneous injection device with an arrow pointing upward, indicating the direction to pull or lift the injector before use.*

FDA Label Image

200 U/ml Ifu Figure R (Image 62)

Instructional illustration showing usage of the NovoFine and NovoTwist pen needles, likely indicating how to attach or remove these needles for subcutaneous injection.*

FDA Label Image

200 U/ml Ifu Figure S (Image 63)

An instructional illustration showing a syringe with a needle attaching or detaching a cap, indicated by arrows pointing to the cap and needle. The image likely demonstrates part of the preparation or use of an injection device for insulin degludec solution, subcutaneous route.*

FDA Label Image

200 U/ml Ifu Figure T (Image 64)

An instructional diagram showing a person using their fingers to peel or remove a protective cap or cover from a small cylindrical object, likely related to preparing an injection device for administration.*

FDA Label Image

Label Image (Lbl500907175)

Insulin Degludec FlexTouch Injection 200 units/mL (U-200) label from A-S Medication Solutions. The label notes storage instructions between 36 to 46 degrees F, protection from light, and includes package contents of three 3 mL prefilled pens. The NDC is 50090-7175.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.